SCHEMBL650791

SCHEMBL650791

CCCCN(Cc1ccc2c(c1)OCO2)Cc1c(-c2ccc(C)s2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.61
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HSP90AA1 P07900 2/20 0.40
HSP90AB1 P08238 2/20 0.40
TSHR P16473 2/20 0.39
TDP1 Q9NUW8 1/20 0.38
ALDH1A1 P00352 4/20 0.38
MAPT P10636 2/20 0.38
HPGD P15428 1/20 0.38
KDM4E B2RXH2 3/20 0.37
MEN1 O00255 1/20 0.37
CASP1 P29466 1/20 0.37
KMT2A Q03164 1/20 0.37
HSD17B10 Q99714 1/20 0.37
F2R P25116 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
MAPK1 P28482 1/20 0.36
PPARG P37231 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649209 0.96 C5AR1 (0.64) C5AR1SMN1; SMN2LMNAL3MBTL1HSP90AA1
SCHEMBL5137882 0.91 C5AR1 (0.71) C5AR1SMN1; SMN2LMNAL3MBTL1HSP90AA1
SCHEMBL5137483 0.88 C5AR1 (0.67) C5AR1SMN1; SMN2LMNAL3MBTL1TSHR
SCHEMBL649868 0.87 C5AR1 (0.66) C5AR1SMN1; SMN2LMNAL3MBTL1TSHR
SCHEMBL651051 0.87 C5AR1 (0.71) C5AR1SMN1; SMN2LMNAL3MBTL1HSP90AA1
SCHEMBL648830 0.86 C5AR1 (0.64) C5AR1SMN1; SMN2LMNAL3MBTL1TSHR
SCHEMBL4767016 0.86 C5AR1 (0.75) C5AR1SMN1; SMN2LMNAL3MBTL1HSP90AA1
SCHEMBL5136055 0.86 C5AR1 (0.65) C5AR1SMN1; SMN2LMNAL3MBTL1HSP90AA1
SCHEMBL5136318 0.86 C5AR1 (0.65) C5AR1SMN1; SMN2LMNAL3MBTL1HSP90AA1
SCHEMBL5135265 0.86 C5AR1 (0.65) C5AR1SMN1; SMN2LMNAL3MBTL1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7786167-B2 Ester derivatives; in vivo saponification by endogenous enzymes; dosage efficiency IDEXX LABORATORIES, INC. (US) 2010-08-31 US claimed
EP-2181706-A2 Florfenicol esters for treating bacterial infections IDEXX LABORATORIES, INC. (US) 2010-05-05 EP claimed
US-20080306152-A1 COMPOSITIONS CONTAINING PRODRUGS OF FLORFENICOL AND METHODS OF USE IDEXX LBORATORIES, INC. (US) 2008-12-11 US claimed
US-20080090912-A1 Compositions containing prodrugs of florfenicol and methods of use MURTHY YERRAMILLI V 2008-04-17 US claimed
EP-1651202-A4 COMPOSITIONS CONTAINING PRODRUGS OF FLORFENICOL AND METHODS OF USE IDEXX LAB INC (US) 2006-08-02 EP claimed
EP-1651202-A1 COMPOSITIONS CONTAINING PRODRUGS OF FLORFENICOL AND METHODS OF USE IDEXX LABORATORIES, INC. (US) 2006-05-03 EP claimed
WO-2005009429-A1 COMPOSITIONS CONTAINING PRODRUGS OF FLORFENICOL AND METHODS OF USE IDEXX LABORATORIES, INC. (US) 2005-02-03 WO claimed
US-20050014828-A1 Compositions containing prodrugs of florfenicol and methods of use IDEXX LABORATORIES, INC. 2005-01-20 US claimed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119667-B2 Carbonates of fenicol antibiotics SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) 2012-02-21 US disclosed
EP-1966129-B1 CARBONATES OF FENICOL ANTIBIOTICS SCHERING PLOUGH LTD (CH) 2011-08-17 EP disclosed
EP-2181706-A3 Florfenicol esters for treating bacterial infections IDEXX LABORATORIES, INC. (US) 2010-10-06 EP disclosed
WO-2005009429-A1 COMPOSITIONS CONTAINING PRODRUGS OF FLORFENICOL AND METHODS OF USE IDEXX LABORATORIES, INC. (US) 2005-02-03 WO disclosed
WO-2005009429-A1 COMPOSITIONS CONTAINING PRODRUGS OF FLORFENICOL AND METHODS OF USE IDEXX LABORATORIES, INC. (US) 2005-02-03 WO disclosed
US-20050014828-A1 Compositions containing prodrugs of florfenicol and methods of use IDEXX LABORATORIES, INC. 2005-01-20 US disclosed
US-20050014828-A1 Compositions containing prodrugs of florfenicol and methods of use IDEXX LABORATORIES, INC. 2005-01-20 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306152-A1 COMPOSITIONS CONTAINING PRODRUGS OF FLORFENICOL AND METHODS OF USE FAP, CYP3A5, CYP4F3 C5AR1 1670/4885SMN1; SMN2 3536/4885LMNA 2883/4885
US-20050014828-A1 Compositions containing prodrugs of florfenicol and methods of use FAP, CYP3A5, CYP4F3 C5AR1 1670/4885SMN1; SMN2 3536/4885LMNA 2883/4885
US-20080090912-A1 Compositions containing prodrugs of florfenicol and methods of use FAP, CYP3A5, CYP4F3 C5AR1 1670/4885SMN1; SMN2 3536/4885LMNA 2883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.